A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma

Trial Profile

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma; Marginal-zone-B-cell-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AUGMENT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 23 Jul 2018 According to a Celgene Corporation media release, data from this study will be submitted to a future medical meeting. This data is planned to be used for the global regulatory submissions in the first quarter of 2019.
    • 23 Jul 2018 Results presented in a Celgene Corporation media release.
    • 23 Jul 2018 Primary endpoint has been met. (Progression free survival (PFS) for indolent lymphoma (Follicular lymphoma and Marginal zone lymphoma), according to a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top